drugset / Trial / NCT07310563
A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity
RandomizedParallel-groupOpen-labelBasic science
Summary
The primary objective of this trial is to evaluate the pharmacokinetics (PK) of AMG 133 administered alone and in combination with an antiemetic medication, ondansetron, in participants living with overweight or obesity.
Timeline
- Start
- 2024-12-10
- Primary completion
- 2025-05-09
- Completion
- 2025-05-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMG 133 | Unknown | 70 mg | Subcutaneous |
| Subject | AMG 133 | Unknown | 350 mg | Subcutaneous |
| Subject | Ondansetron | Other / unclassified | 8 mg | Oral |